PlusTherapeuticsInc . (NASDAQ:PSTV) saw a large drop in short interest in January. As of January 31st, there was short interest totalling 53,000 shares, a drop of 20.3% from the January 15th total of 66,500 shares. Based on an average daily volume of 357,400 shares, the short-interest ratio is presently 0.1 days. Currently, 1.5% of the shares of the stock are short sold.
Shares of PSTV traded down $0.04 during mid-day trading on Friday, reaching $2.12. The company had a trading volume of 43,426 shares, compared to its average volume of 103,314. The business’s 50 day moving average price is $2.46. PlusTherapeuticsInc . has a 1-year low of $1.78 and a 1-year high of $22.89. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 4.28. The company has a market cap of $7.96 million, a P/E ratio of -0.06 and a beta of 1.74.
PlusTherapeuticsInc . (NASDAQ:PSTV) last posted its quarterly earnings results on Thursday, November 14th. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($5.85) by $5.82. PlusTherapeuticsInc . had a negative net margin of 203.18% and a negative return on equity of 1,037.22%. The company had revenue of $4.77 million for the quarter.
Several institutional investors and hedge funds have recently bought and sold shares of PSTV. Sabby Management LLC acquired a new stake in shares of PlusTherapeuticsInc . in the 3rd quarter valued at approximately $389,000. Renaissance Technologies LLC boosted its stake in shares of PlusTherapeuticsInc . by 146.6% in the 4th quarter. Renaissance Technologies LLC now owns 85,634 shares of the company’s stock valued at $206,000 after purchasing an additional 50,903 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in PlusTherapeuticsInc . during the 4th quarter worth approximately $69,000. Oxford Asset Management LLP acquired a new stake in PlusTherapeuticsInc . during the 4th quarter worth approximately $50,000. Finally, Virtu Financial LLC acquired a new stake in PlusTherapeuticsInc . during the 4th quarter worth approximately $35,000. Institutional investors own 10.61% of the company’s stock.
About PlusTherapeuticsInc .
Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, engages in developing treatments for cancer and other diseases in the United States. The company's lead product candidate in pipeline is DocePLUS, an albumin-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer.
See Also: Cost of Goods Sold (COGS)
Receive News & Ratings for PlusTherapeuticsInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PlusTherapeuticsInc . and related companies with MarketBeat.com's FREE daily email newsletter.